Developing VLP (Virus like particle) based nano-particulate HPV ( | 4007
Drug Designing: Open Access

Drug Designing: Open Access
Open Access

ISSN: 2169-0138

+44 1223 790975

Developing VLP (Virus like particle) based nano-particulate HPV (Human papillomavirus) vaccine for cervical cancer

International Conference and Expo on Drug Discovery & Designing

August 11-13, 2015 Frankfurt, Germany

Mohammad Nasir Uddin

Posters-Accepted Abstracts: Drug Des

Abstract :

Cervical cancer is the second most cause of cancer related death among women all over the world. Two HPV type-specific
prophylactic vaccines are currently being used world-wide. However, the cost of the vaccine itself, the expensive storage system,
need for an expert to administer the vaccines tremendously inhibits the global use of the vaccines. Moreover recent controversy over
the side effects of both vaccines also calls for a demand to develop an alternative vaccine which will be able to address all the issues.
The goal of this project is to develop a nano particulate VLP based HPV vaccine that will be cost effective, highly potent and can be
used in resource poor countries. The VLP containing particulate vaccines were prepared in a simple one step spray drying process
using a Eudragit polymer. The size, shape and surface morphology of the particles were determined by scanning electron microscopy
(SEM). Within the particle, the presence of VLP was detected using SDS-PAGE analysis and quantified using Western blot. The
functionality of the vaccine was tested in an in vivo animal model using Swiss Webster mice. The antibody obtained from serum
was analyzed by ELISA. The presence of intact VLPs was confirmed by TEM images. The animal study showed the significantly high
titer. Based on these primary results we envision that the current formulation would offer mucosal and systemic protection by taking
the advantages of particulate form of vaccines at multiple anatomic sites that are vulnerable to HPV infection and associated disease